Kantil Pharmaceuticals Private Limited, a active private limited company, was established on 08 October 2021 in Delhi, Delhi, India. Engaging in drug formulation & development within the manufacturing sector, it holds CIN: U24230DL2021PTC387973. Registered under ROC Roc Delhi. it is unlisted. It has an authorized capital of ₹3.50 M and a paid-up capital of ₹3.50 M.
It upholds a compliant status. Employing 33 professional, Its leadership includes Nitin Gupta (Director), Shikha (Director), Sarika Gupta (Director). Past directors included Sachin Gupta, Sarika Gupta. It holds ₹19.27 Cr open charges and ₹12.75 Cr settled loans. Its latest AGM occurred on 30 September 2024, with the balance sheet filed on 31 March 2024. It is based at 5, Raj Nagar, Pitam Pura, Delhi, Delhi, 110034.
U24230DL2021PTC387973
387973
08 October 2021
₹3.50 M
₹3.50 M
Roc Delhi
Unlisted
Active
Explore comprehensive insights into Kantil Pharmaceuticals Private Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Nitin Gupta | Director | 08 Oct 2021 | Current |
| Shikha | Director | 08 Oct 2021 | Current |
| Sarika Gupta | Director | 08 Apr 2022 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Additional Director | 30 Sep 2022 | Past |
| Pramod Abcsdd | Additional Director | 30 Sep 2022 | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Kantil Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 104.73% increase. The company also saw a substantial fall in profitability, with a 9434.03% decrease in profit. The company's net worth observed a substantial decline by a decrease of 858.86%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
Unlock access to Kantil Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Reveal ownership structures and financial performance - Get instant access now!
₹192,749,000.00
₹127,500,000.00
| Date | Lender | Amount | Status |
|---|---|---|---|
| 27 Mar 2025 | Others | ₹11.50 Cr | Open |
| 27 Mar 2025 | Others | ₹5.00 Cr | Open |
| 04 Mar 2023 | Hdfc Bank Limited | ₹0.73 M | Open |
| 06 Oct 2022 | Hdfc Bank Limited | ₹2.70 Cr | Open |
| 29 Mar 2022 | Hdfc Bank Limited | ₹12.75 Cr | Satisfied |
Explore comprehensive loan charge details -
Unlock and access historical data on people associated with Kantil Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Gain comprehensive insights into the Deals and Valuation data of Kantil Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Kantil Pharmaceuticals's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
The activity A charge registered on 29 Mar 2022 via Charge ID 100563338 with Hdfc Bank Limited was fully satisfied on 22 Jul 2025. was completed.
A charge with Others amounted to Rs. 115.02 M with Charge ID 101078274 was registered on 27 Mar 2025. was recorded as a recent event.
The activity A charge with Others amounted to Rs. 50.00 M with Charge ID 101078260 was registered on 27 Mar 2025. was completed.
Kantil Pharmaceuticals Private Limited last Annual general meeting of members was held on 30 Sep 2024 as per latest MCA records. was recorded as a recent event.
The activity Kantil Pharmaceuticals Private Limited has filed its annual Financial statements for the year ended 31 Mar 2024 with Roc Delhi. was completed.
Progress on A charge with Hdfc Bank Limited of Rs. 127.50 M registered on 29 Mar 2022 with Charge ID 100563338 was modified on 30 Jan 2024. was documented.
The CIN of Kantil Pharmaceuticals Private Limited is U24230DL2021PTC387973.
Kantil Pharmaceuticals Private Limited is headquartered at 5, Raj Nagar, Pitam Pura, Delhi, Delhi, 110034.
Kantil Pharmaceuticals Private Limited was incorporated on 08 October 2021.
The current directors of Kantil Pharmaceuticals Private Limited are
The primary industry of Kantil Pharmaceuticals Private Limited is Manufacturing.
Kantil Pharmaceuticals Private Limited is unlisted.
The authorized capital of Kantil Pharmaceuticals Private Limited is ₹3.50 M, and the paid-up capital is ₹3.50 M.
The compliance status of Kantil Pharmaceuticals Private Limited is Compliant.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX